Semax
A synthetic peptide approved as a medicine in Russia; not FDA-approved in the United States.
What it is
Semax is Selank's better-known sibling — a synthetic fragment related to ACTH, developed in Russia and holding Russian approval for uses that include stroke recovery and cognitive complaints.
It has decades of Russian clinical literature behind it and essentially no Western regulatory review. The nootropic community adopted it enthusiastically; the evidence a US reader would want — independent randomized trials — doesn't exist.
What researchers have actually studied it for
Stroke recovery and cognitive indications in Russian clinical practice and literature; no FDA review or approval.
How it works
A fragment of ACTH(4-10) with a stabilizing extension, stripped of hormonal (cortisol-stimulating) activity. Proposed actions center on boosting BDNF and modulating dopaminergic and serotonergic signaling — a neurotrophic-support story, built mostly on animal work and Russian clinical series.
The molecule itself
A heptapeptide: ACTH's 4-7 fragment (MEHF) plus the same PGP stabilizing tail as Selank — sibling engineering from the same institute. The design keeps ACTH's neuroactive core while shedding adrenal (cortisol) activity, delivered intranasally for the same bioavailability reasons.
Where it came from
Developed by Moscow institutes in the 1980s–90s and registered in Russia in 1996 for stroke and cognitive indications, Semax is standard in Russian neurology — famously in ambulances — while remaining essentially invisible to Western regulators. The nootropics community bridges that gap by mail order.
The timeline
1980s
Designed at Moscow institutes from ACTH fragment research.
1996
Registered in Russia for stroke and cognitive indications.
2000s
Enters Russian emergency-medicine protocols.
2010s+
Western nootropic adoption; zero Western trials.
What the research record actually contains
- Russian clinical studies in stroke recovery and cognitive impairment reporting benefit.
- Animal literature on BDNF elevation and neuroprotection.
- No independent Western RCTs; healthy-adult enhancement — its internet use case — is untested anywhere.
What could change this assessment
Its scientific future is wherever Russian neurology takes it; Western data is not coming absent a sponsor with approval ambitions. For readers, the file is stable: interesting, regional, untranslated.
What's known about risks
Reported as well tolerated in Russian practice. No independent characterization; short-term nasal use appears benign in that literature, and the honest phrase remains 'insufficiently studied by independent groups.'
Where it stands legally
A registered Russian medicine; unapproved and unreviewed in the US, circulating through gray-market import.
Worth asking a licensed provider
- 1.For cognitive complaints, what established work-up should come before any compound — sleep, thyroid, depression, medications?
- 2.How should I weigh an evidence base that exists only in another country's literature?
- 3.If neuroprotection interests me, what proven strategies do we have?
Common claims, corrected
“It's a study drug like modafinil.”
Reality: Modafinil has Western trials in defined populations; Semax has Russian clinical studies in stroke and impairment. Neither has meaningful healthy-adult enhancement data, but only one has crossed regulatory review at all.
“The BDNF mechanism guarantees cognitive benefit.”
Reality: BDNF elevation is animal-model evidence and mechanism-talk; enhancement outcomes in healthy humans have never been measured for it anywhere.
Semax FAQ
Does Semax improve memory or focus?
Russian studies report cognitive benefits in clinical populations. Whether it enhances cognition in healthy adults has not been established in independent controlled trials — which is precisely the claim nootropic marketing makes.
Is Semax legal in the US?
It is not an approved drug and isn't lawfully sold as a supplement; it circulates as a gray-market import, typically as a nasal spray.
Semax vs Selank — what's the difference?
Different parent molecules and different Russian indications: Semax skews cognitive/neurological, Selank anti-anxiety. They share the same evidence limitation — Russian-language literature without independent replication.
Is Semax used in actual Russian hospitals?
Yes — it appears in Russian stroke protocols and emergency use, a real clinical role within that system. Clinical adoption there and evidence sufficiency here are separate questions.
Semax vs Noopept?
Different molecules from the same regional tradition: Noopept is an oral dipeptide-derivative, Semax an intranasal ACTH fragment. They share the category's defining feature — regional files, no healthy-adult enhancement trials.